NMC
RANI icon

Nine Masts Capital’s Rani Therapeutics RANI Stock Holding History

Nine Masts Capital’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-44,849
Closed -$33K – 273
2026
Q1 		$33K Buy
+44,849
New +$57.3K ﹤0.01% 209

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nine Masts Capital's RANI Position: Q2 2026 in Review

Nine Masts Capital sold out of Rani Therapeutics (RANI) in Q2 2026, closing a stake of 44,849 shares — an estimated $33K sold.

Nine Masts Capital first reported a position in RANI in Q1 2026 and held it in 1 quarter. The position peaked at $33K in Q1 2026. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Nine Masts Capital reported no remaining Rani Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Nine Masts Capital sold 44,849 Rani Therapeutics shares in Q2 2026, an estimated $33K.
  • Nine Masts Capital first reported a position in Rani Therapeutics in Q1 2026 and held it in 1 quarter.
  • Nine Masts Capital's Rani Therapeutics position peaked at $33K in Q1 2026.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.